DGAP-Adhoc: LifeWatch AG: BioTelemetry, Inc. publiziert Angebotsprospekt für das öffentliche Übernahmeangebot an LifeWatch AG

LifeWatch AG: BioTelemetry, Inc. publiziert Angebotsprospekt für das öffentliche Übernahmeangebot an LifeWatch AG

^

EQS Group-Ad-hoc: LifeWatch AG / Schlagwort(e): Übernahmeangebot

LifeWatch AG: BioTelemetry, Inc. publiziert Angebotsprospekt für das

öffentliche Übernahmeangebot an LifeWatch AG

24.04.2017 / 23:00 CET/CEST

Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR

---------------------------------------------------------------------------

BioTelemetry, Inc. publiziert Angebotsprospekt für das öffentliche

Übernahmeangebot an LifeWatch AG

Der Verwaltungsrat von LifeWatch unterstützt das Angebot von BioTelemetry

Zug/Schweiz und Malvern/USA, 24. April 2017 - LifeWatch AG (SIX:LIFE) und

BioTelemetry Inc. (NASDAQ:BEAT), geben bekannt, dass BioTelemetry heute den

Angebotsprospekt für das öffentliche Übernahmeangebot für alle ausstehenden

Namensaktien von LifeWatch AG publiziert hat. Die Aktionäre von LifeWatch

werden entweder CHF 10.00 in bar und 0.1457 Aktien von BioTelemetry

(Hauptangebot) (entspricht CHF 4.00 pro LifeWatch-Aktie, basierend auf dem

Schlusskurs von BioTelemetry am Freitag, 7. April 2017) oder CHF 8.00 in bar

und 0.2185 Aktien von BioTelemetry (Alternativangebot) (entspricht CHF 6.00

pro LifeWatch-Aktie, basierend auf dem Schlusskurs von BioTelemetry am

Freitag, 7. April 2017) erhalten, je nach individueller Präferenz des

Aktionärs. Basierend auf dem Aktienpreis vom 7. April 2017 beläuft sich der

Gesamtwert der Übernahme auf ca. CHF 260 Millionen. Der Verwaltungsrat von

LifeWatch unterstützt das öffentliche Übernahmeangebot von BioTelemetry und

empfiehlt den Aktionären dessen Annahme.

Unter Berücksichtigung des Schlusskurses der BioTelemetry-Aktie vom 20.

April 2017 - zwei Handelstage vor der Publikation des Angebotsprospekts -

entspricht das Angebot einem Gegenwert von CHF 14.56 (Hauptangebot)

beziehungsweise CHF 14.84 (Alternativangebot) pro LifeWatch-Aktie. Durch den

Anstieg des Aktienpreises von BioTelemetry seit der ursprünglichen

Ankündigung am 9. April 2017 ist der Gesamtwert der Übernahme auf CHF 269 -

275 Millionen gestiegen.

Weitere Informationen finden sich im Bericht des Verwaltungsrats von

LifeWatch sowie der von der Raiffeisen erstellten Fairness Opinion unter

www.lifewatch.com/public-tender-offer-Cardiac-Monitoring.html, dem

Angebotsprospekt von BioTelemetry unter https://www.gobio.com/ sowie der

Website des Swiss Takeover Boards www.takeover.ch.

Gemäss dem Zeitplan beginnt die Hauptangebotsfrist am 10. Mai 2017 und läuft

voraussichtlich bis am 23. Mai 2017, unter Vorbehalt einer

Fristverlängerung.

Für Rückfragen:

LifeWatch AG, Andrew Moore, CFO

c/o Communicators AG, Ralph Spillmann

Mobile: +41 79 514 64 84

E-Mail: investor-relations@lifewatch.com

Zu LifeWatch AG

LifeWatch AG, mit Hauptsitz in Zug und Kotierung an der SIX Swiss Exchange

(LIFE) in der Schweiz, ist ein führender Anbieter von ferngesteuerten

diagnostischen "Digital Health" Dienstleistungen. Die Dienstleistungen von

LifeWatch liefern den Ärzten wichtige Informationen zur angemessenen

Behandlung ihrer Patienten mit dem Ziel, die Behandlung zu optimieren.

LifeWatch AG verfügt über operative Tochtergesellschaften in den USA, der

Schweiz, Israel und der Türkei und ist die Muttergesellschaft von LifeWatch

Services, Inc., LifeWatch Technologies Ltd. und LifeWatch Turkey Holding AG

(Joint Venture). LifeWatch Services, Inc. ist ein führender US-Anbieter für

Herzüberwachungsdienstleistungen. LifeWatch Technologies Ltd. in Israel ist

ein führender Hersteller von Digital-Health-Produkten. LifeWatch Salk

Hizmetlerine A.S. ist die operative Tochtergesellschaft der LifeWatch Turkey

Holding AG und Anbieter von Herzüberwachungsdienstleistungen in der Türkei.

Für weitere Informationen: siehe www.lifewatch.com.

Zu BioTelemetry

BioTelemetry, Inc., früher als CardioNet bekannt, ist ein führendes

Unternehmen im Bereich kabelloser Medizinaltechnologie. Der Fokus liegt auf

der Bereitstellung von Gesundheitsdaten zur Verbesserung der Lebensqualität

sowie zur Reduktion der Gesundheitskosten. Das Unternehmen bietet zurzeit

Herzüberwachungs-Dienstleistungen an und produziert Geräte mit einem

primären Fokus auf die Herzüberwachung sowie zentralisierte Dienstleistungen

für Herzlaboratorien. Für weitere Informationen: siehe www.biotelinc.com.

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements regarding, among

other things, statements about both BioTelemetry's and LifeWatch's beliefs

and expectations, statements about BioTelemetry's proposed acquisition of

LifeWatch AG, including the timing and success of the tender offer and

expectations regarding the growth and success of the combined entity. These

statements may be identified by words such as "expect," "anticipate,"

"estimate," "intend," "plan," "believe," "promises", "projects," and other

words and terms of similar meaning. Such forward-looking statements are

based on current expectations and involve inherent risks and uncertainties,

including important factors that could delay, divert, or change any of these

expectations, and could cause actual outcomes and results to differ

materially from current expectations. Factors that may materially affect

such forward-looking statements include: BioTelemetry's ability to

successfully complete the tender offer for LifeWatch's shares or realize the

anticipated benefits of the transaction; and the failure of any of the

conditions to BioTelemetry's tender offer to be satisfied. For further

details and a discussion of these and other risks and uncertainties, please

see BioTelemetry's public filings with the Securities and Exchange

Commission, including the company's latest periodic reports on Form 10-K and

10-Q respectively, LifeWatch's past press releases, reports and other

information posted on LifeWatch's website. Readers are cautioned not to put

undue reliance on forward-looking statements, which reflect only opinions as

of the date of this press release. BioTelemetry and LifeWatch do not

undertake, and specifically disclaim, any obligation to publicly update or

amend any forward-looking statement, whether as a result of new information,

future events, or otherwise.

OFFER RESTRICTIONS

The public tender offer described in the offer documents (the "Offer") is

not being and will not be made, directly or indirectly, in any country or

jurisdiction in which it would be considered unlawful or otherwise violate

any applicable laws or regulations, or which would require BioTelemetry or

any of its subsidiaries to change or amend the terms or conditions of the

Offer in any material way, to make an additional filing with any

governmental, regulatory or other authority or take additional action in

relation to the Offer. It is not intended to extend the Offer to any such

country or jurisdiction. Any such documents relating to the Offer must

neither be distributed in any such country or jurisdiction nor be sent into

such country or jurisdiction, and must not be used for the purpose of

soliciting the purchase of securities of LifeWatch by any person or entity

resident or incorporated in any such country or jurisdiction.

NOTICE TO U.S. PERSONS HOLDING LIFEWATCH SHARES

The Offer is made for the securities of a non-U.S. company. The Offer is

subject to the disclosure and procedural requirements of Switzerland, which

are different from those of the United States (the "U.S.").

The Offer may not be accepted before expiration of a cooling-off period of

ten (10) trading days, which will run from April 25, 2017 through May 9,

2017, unless extended by the Swiss Takeover Board.

According to the laws of Switzerland, LifeWatch shares tendered into the

Offer may be withdrawn after they are tendered until the expiration of the

main offer period.

BioTelemetry and any of its subsidiaries and any advisor, broker or

financial institution acting as an agent or for the account or benefit of

BioTelemetry or the Offeror may, subject to applicable Swiss securities

laws, rules and regulations, make certain purchases of, or arrangements to

purchase, LifeWatch shares from shareholders of LifeWatch who are willing to

sell their LifeWatch shares outside the Offer from time to time, including

purchases in the open market at prevailing prices or in private transactions

at negotiated prices. The Offeror will disclose promptly any information

regarding such purchases of LifeWatch shares in Switzerland through the

electronic media and/or the stock exchange and in the U.S. by means of a

press release, if and to the extent required under applicable laws, rules

and regulations in Switzerland.

It may be difficult for U.S. holders to enforce their rights and any claim

arising out of U.S. federal securities laws, since LifeWatch is located in a

non-U.S. jurisdiction, and some or all of its officers and directors may be

residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a

non-U.S. company or its officers or directors in a non-U.S. court for

violations of the U.S. securities laws. Further, it may be difficult to

compel a non-U.S. company and its affiliates to subject themselves to a U.S.

court's judgment.

The receipt of cash and stock consideration in the Offer by a U.S.

shareholder will generally be a taxable transaction for U.S. federal, state

and local income tax purposes. Each U.S. shareholder is urged to consult his

independent professional adviser immediately regarding the tax consequences

of acceptance of the Offer.

Securities may not be offered or sold in the U.S. absent registration or an

exemption from registration under the U.S. Securities Act. It is expected

that the Offer will be subject to a Tier I exemption pursuant to Rule

14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that

the issuance of BioTelemetry Common Stock in connection therewith will be

exempt from registration under the U.S. Securities Act of 1933, as amended,

pursuant to Rule 802 thereof.

Neither the Securities and Exchange Commission nor any securities commission

of any State of the U.S. has (a) approved or disapproved of the Offer, (b)

passed upon the merits or fairness of the Offer, or (c) passed upon the

adequacy or accuracy of the disclosure in the pre-announcement. Any

representation to the contrary is a criminal offense in the U.S.

Im Zweifelsfall gilt die englische Originalmeldung.

Zusatzmaterial zur Meldung:

Dokument: http://n.eqs.com/c/fncls.ssp?u=PKFUTDXLGJ

Dokumenttitel: BioTelemetry, Inc. publiziert Angebotsprospekt für das

öffentliche Übernahmeangebot an LifeWatch AG

---------------------------------------------------------------------------

Ende der Ad-hoc-Mitteilung

---------------------------------------------------------------------------

Sprache: Deutsch

Unternehmen: LifeWatch AG

Baarerstrasse 139

6300 Zug

Schweiz

Telefon: +41 41 728 67 78

Internet: www.lifewatch.com

ISIN: CH0012815459

Valorennummer: 811189

Börsen: Freiverkehr in Berlin, Stuttgart; Open Market in

Frankfurt; SIX Swiss Exchange

Ende der Mitteilung EQS Group News-Service

---------------------------------------------------------------------------

566933 24.04.2017 CET/CEST

°